{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:23Z","timestamp":1778728043361,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.leukres.2026.108228","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:11:06Z","timestamp":1775689866000},"page":"108228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation"],"prefix":"10.1016","volume":"165","author":[{"given":"Daniel","family":"Sch\u00fctte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Call","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"F\u00fcrstenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"d'Hargues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas P.","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108228_bib1","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib2","unstructured":"SEER*Explorer Application. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0."},{"key":"10.1016\/j.leukres.2026.108228_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108228_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108228_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the american society of transplantation and cellular therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.leukres.2026.108228_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2","volume":"19","author":"Pollyea","year":"2021","journal-title":"2021. J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"10.1016\/j.leukres.2026.108228_bib9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib10","doi-asserted-by":"crossref","first-page":"767.e1","DOI":"10.1016\/j.jtct.2022.08.008","article-title":"Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis","volume":"28","author":"Kharfan-Dabaja","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.leukres.2026.108228_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.leukres.2026.108228_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beha.2016.10.011","article-title":"The role of second transplants for leukemia","volume":"29","author":"Weisdorf","year":"2016","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2026.108228_bib14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","article-title":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation","volume":"108","author":"Yerushalmi","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108228_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108228_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib17","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","article-title":"Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia","volume":"27","author":"Yalniz","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.leukres.2026.108228_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108228_bib20","doi-asserted-by":"crossref","first-page":"905.e1","DOI":"10.1016\/j.jtct.2024.06.019","article-title":"Second allogeneic hematopoietic cell transplantation for relapsed adult acute myeloid leukemia: outcomes and prognostic factors","volume":"30","author":"Rodr\u00edguez-Arbol\u00ed","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.leukres.2026.108228_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108228_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from the german cooperative transplant study group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib23","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2018-99-112025","article-title":"Functional status is associated with outcomes after allogeneic stem cell transplantation for older patients with hematologic malignancies","volume":"132","author":"Huang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108228_bib24","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108228_bib25","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108228_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib27","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.bbmt.2018.12.076","article-title":"Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib28","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.bbmt.2013.12.038","article-title":"Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome","volume":"20","author":"Tamari","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108228_bib30","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108228_bib31","first-page":"16437","article-title":"Second allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia: a retrospective single-center analysis of the outcome","volume":"133","author":"\u0141ojko","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.leukres.2026.108228_bib32","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","article-title":"Evaluation of trends and prognosis over time in patients with aml relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years","volume":"26","author":"Bazarbachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2026.108228_bib33","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","article-title":"The Graft-Versus-Leukemia Effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108228_bib34","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:07:11Z","timestamp":1778724431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262600072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S014521262600072X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108228","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108228"}}